Business Context and Reporting Period
This Form 8-K filing by Calyxt, Inc. (noting the metadata reference to Cibus, Inc. appears to be a discrepancy as the filing text explicitly names Calyxt, Inc.) reports a significant executive leadership change. The report date is September 17, 2018, with the effective date of the new appointment set for October 1, 2018.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new executive employment agreement.
Material Changes
The primary material change is the appointment of James Blome as Chief Executive Officer, replacing Yves Ribeill, Ph.D., who served as interim CEO. Mr. Ribeill will remain on the Board of Directors. Mr. Blome brings extensive experience from Bayer CropScience, LP, where he served as President and CEO for North America since 2011.
Compensation, Outlook, and Risks
The filing details a comprehensive compensation package for Mr. Blome, effective October 1, 2018:
- Base Salary: $635,000 annually.
- Sign-on Bonus: $1,000,000 one-time payment, subject to repayment if employment ends within one year.
- Performance Bonus: Target of 75% of base salary, prorated for 2018.
- Relocation: Up to $125,000 for expenses, plus a $10,000 household goods payment and up to $20,000 for tax gross-ups.
- Equity Grants (Initial): 180,000 Restricted Stock Units (RSUs) granted immediately as a consultant, with a vesting schedule starting October 1, 2018. Additionally, 200,000 stock options will be granted within 30 days of employment.
- Annual Equity: Eligibility for 50,000 RSUs and 125,000 stock options annually, subject to performance metrics.
- Severance:
- Without Cause (Pre-Change in Control): 18 months' base salary (24 months after year one) plus pro-rata bonus and maximum annual bonus target.
- Without Cause/Good Reason (Post-Change in Control): 24 months' base salary plus two times the maximum annual performance bonus.
The filing does not contain specific forward-looking guidance on company operations, risks, or contingencies beyond the standard terms of the employment agreement.
Investor Verification Checklist
- Verify the correct registrant name (Calyxt, Inc. vs. Cibus, Inc.) to ensure accurate tracking of filings.
- Confirm the vesting schedule and performance metrics for the 180,000 initial RSUs and 200,000 initial stock options.
- Review the specific definitions of "Cause," "Good Reason," and "Change in Control" in the attached Employment Agreement (Exhibit 10.1) to understand severance triggers.
- Monitor the impact of the $1,000,000 sign-on bonus and annual compensation on the company's cash burn rate and future dilution.